JP2006502243A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502243A5
JP2006502243A5 JP2005501197A JP2005501197A JP2006502243A5 JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5 JP 2005501197 A JP2005501197 A JP 2005501197A JP 2005501197 A JP2005501197 A JP 2005501197A JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oligodeoxynucleotide
effective
use according
clusterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005501197A
Other languages
English (en)
Japanese (ja)
Other versions
JP4620585B2 (ja
JP2006502243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2003/001276 external-priority patent/WO2004018675A1/en
Publication of JP2006502243A publication Critical patent/JP2006502243A/ja
Publication of JP2006502243A5 publication Critical patent/JP2006502243A5/ja
Application granted granted Critical
Publication of JP4620585B2 publication Critical patent/JP4620585B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005501197A 2002-08-21 2003-08-21 クラステリンレベルを減少させることによる黒色腫の治療 Expired - Fee Related JP4620585B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (3)

Publication Number Publication Date
JP2006502243A JP2006502243A (ja) 2006-01-19
JP2006502243A5 true JP2006502243A5 (enExample) 2007-11-08
JP4620585B2 JP4620585B2 (ja) 2011-01-26

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501197A Expired - Fee Related JP4620585B2 (ja) 2002-08-21 2003-08-21 クラステリンレベルを減少させることによる黒色腫の治療

Country Status (16)

Country Link
US (1) US7285541B2 (enExample)
EP (1) EP1530636B1 (enExample)
JP (1) JP4620585B2 (enExample)
KR (1) KR101052289B1 (enExample)
AT (1) ATE478142T1 (enExample)
AU (1) AU2003258425B2 (enExample)
CA (1) CA2494764C (enExample)
CY (1) CY1110936T1 (enExample)
DE (1) DE60333839D1 (enExample)
DK (1) DK1530636T3 (enExample)
IL (1) IL166657A (enExample)
NO (1) NO333254B1 (enExample)
NZ (1) NZ538288A (enExample)
PT (1) PT1530636E (enExample)
SI (1) SI1530636T1 (enExample)
WO (1) WO2004018675A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP4491240B2 (ja) 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
CA2494764C (en) 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
EP1532249A2 (en) 2002-08-21 2005-05-25 The University of British Columbia Rnai probes targeting cancer-related proteins
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
EP1937815B1 (en) 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
WO2009028968A1 (en) * 2007-08-28 2009-03-05 Auckland Uniservices Limited Cell marker of melanocyte cell lineage and uses thereof
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US20140275215A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Anti-clusterin monotherapy for cancer treatment
CN119604763A (zh) * 2022-01-26 2025-03-11 艾德克斯实验室公司 用于区分进展性慢性肾脏疾病与稳定性慢性肾脏疾病的方法和组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
JP2002510644A (ja) * 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
AU2730801A (en) 1999-12-21 2001-07-03 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP4491240B2 (ja) 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
EP1532249A2 (en) 2002-08-21 2005-05-25 The University of British Columbia Rnai probes targeting cancer-related proteins
CA2494764C (en) 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Similar Documents

Publication Publication Date Title
JP2006502243A5 (enExample)
JP7116212B2 (ja) Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP6649248B2 (ja) 細胞取り込みの向上のための化合物および方法
DK2850186T3 (en) COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
ES2657679T3 (es) Modulación del factor de expresión 11
AU2014306284B2 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
CN113164509A (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
WO2013173637A1 (en) Compositions and methods for modulating gene expression
JP6487913B2 (ja) 成長ホルモン受容体のモジュレータ
CA2873769A1 (en) Compositions and methods for modulating hemoglobin gene family expression
JP2016513976A5 (enExample)
JP6290316B2 (ja) ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2004509970A5 (enExample)
EA035756B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
JP2018530325A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
CN113293163A (zh) 用于调节载脂蛋白c-iii表达的组合物和方法
JP2010512747A5 (enExample)
JP2003531915A (ja) ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
KR20150004414A (ko) Kras-관련 질환을 치료하기 위한 유기 조성물
CN104011209A (zh) 病毒基因表达的抑制
CN110536965B (zh) 用于抑制男性型脱发靶基因表达的不对称siRNA
JP2008520591A5 (enExample)
CN118202053A (zh) 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途
JPWO2003025173A1 (ja) Ｃ型肝炎ウイルスに対する新規なアンチセンスオリゴヌクレオチド誘導体